Covid19 clinical trials

Explore recruiting covid19 clinical trials.

Recruiting covid19 studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Covid19 trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

COVID-19 vaccine immunological studies in Finland

Finland

Therapeutic use (Phase IV) EU CTIS Study details

Clinical trial on the virucidal activity of different oral antiseptics against respiratory viruses.

Spain

Therapeutic use (Phase IV) EU CTIS Study details

I4V-MC-KHAB: A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients From 1 Year to Less Than 18 Years Old Hospitalized With COVID-19

Belgium, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Venetoclax in combination with the BTK inhibitor Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with treatment naive Mantle Cell Lymphoma not eligible for high dose therapy

Germany, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

VEMURAFENIB PLUS RITUXIMAB AS A CHEMOTHERAPY-FREE ALTERNATIVE TO CLADRIBINE FOLLOWED BY MRD-GUIDED RITUXIMAB IN FRONT-LINE HAIRY CELL LEUKEMIA (HCL): A PHASE-2 RANDOMIZED MULTICENTER TRIAL

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

PREV-CART - A multicentric phase III randomized clinical trial open-label, comparing immunoglobulin replacement therapy (IgRT) and antibiotic prophylaxis (AP) in patients treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B cell acute lymphoblastic leukemia or a B cell lymphoma

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Covid19 trials by city

Covid19 in Toronto Covid19 in Vancouver Covid19 in Montreal Covid19 in Calgary Covid19 in Edmonton Covid19 in Ottawa Covid19 in Winnipeg Covid19 in Quebec City Covid19 in Hamilton Covid19 in Kitchener Covid19 in London Covid19 in Halifax Covid19 in New York Covid19 in Los Angeles Covid19 in Chicago Covid19 in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease